XML 88 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value measurements (Tables)
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of assets and liabilities measured at fair value on a recurring basis
The following table sets forth the assets that we measure at fair value on a recurring basis by level in the fair value hierarchy (in thousands). There were no liabilities measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022. In addition, there were no transfers of assets measured at fair value on a recurring basis to or from Level 3 in the fair value hierarchy during the nine months ended September 30, 2023.

Fair Value Measurement Using
Description TotalQuoted Prices in
Active Markets
for Identical Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Investments in publicly traded companies:
As of September 30, 2023$129,586 $129,586 $— $— 
As of December 31, 2022$207,139 $207,139 $— $— 
Schedule of assets and liabilities measure at fair value on a nonrecurring basis
The following table sets forth the assets measured at fair value on a nonrecurring basis by level within the fair value hierarchy as of September 30, 2023 and December 31, 2022 (in thousands). These investments were measured at various times during the period from January 1, 2018 to September 30, 2023.
Fair Value Measurement Using
Description TotalQuoted Prices in
Active Markets
for Identical Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)(1)
Significant
Unobservable
Inputs
(Level 3)(2)
Investments in privately held entities that do not report NAV
As of September 30, 2023$200,370 $— $181,726 $18,644 
As of December 31, 2022$212,262 $— $193,784 $18,478 
(1)These amounts represent the total carrying amounts of our equity investments in privately held entities with observable price changes, which are included in the investments balance of $1.4 billion and $1.6 billion, respectively, in our unaudited consolidated balance sheets as of September 30, 2023 and December 31, 2022. For more information, refer to Note 7 – “Investments” to our unaudited consolidated financial statements.
(2)These amounts are included in the investments in privately held entities without observable price changes balances aggregating $387.8 million and $388.9 million as of September 30, 2023 and December 31, 2022, respectively, disclosed in Note 7 – “Investments” to our unaudited consolidated financial statements. The aforementioned balances represent the carrying amounts of investments in privately held entities that do not report NAV for which impairments have been recognized in accordance with the measurement alternative guidance described in the “Investments” section in Note 2 – “Summary of significant accounting policies” to our unaudited consolidated financial statements.
As of September 30, 2023 and December 31, 2022, the book and estimated fair values of our secured notes payable and unsecured senior notes payable and the amounts outstanding under our unsecured senior line of credit and commercial paper program, including the level within the fair value hierarchy for which the estimates were derived, were as follows (in thousands):
September 30, 2023
Book ValueFair Value HierarchyEstimated Fair Value
Quoted Prices in
Active Markets
for Identical Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Liabilities:
Secured notes payable$109,110 $— $108,299 $— $108,299 
Unsecured senior notes payable$11,093,725 $— $8,902,593 $— $8,902,593 
Unsecured senior line of credit
$— $— $— $— $— 
Commercial paper program$— $— $— $— $— 

December 31, 2022
Book ValueFair Value HierarchyEstimated Fair Value
Quoted Prices in
Active Markets
for Identical Assets
(Level 1)
Significant
Other
Observable Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Liabilities:
Secured notes payable$59,045 $— $58,811 $— $58,811 
Unsecured senior notes payable$10,100,717 $— $8,539,015 $— $8,539,015 
Unsecured senior line of credit
$— $— $— $— $— 
Commercial paper program$— $— $— $— $—